These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287 [TBL] [Abstract][Full Text] [Related]
12. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine. Rudenko L; Kiseleva I; Naykhin AN; Erofeeva M; Stukova M; Donina S; Petukhova G; Pisareva M; Krivitskaya V; Grudinin M; Buzitskaya Z; Isakova-Sivak I; Kuznetsova S; Larionova N; Desheva J; Dubrovina I; Nikiforova A; Victor JC; Neuzil K; Flores J; Tsvetnitsky V; Kiselev O PLoS One; 2014; 9(2):e87962. PubMed ID: 24533064 [TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(αK): A phase I study. Pan SC; Hsieh SM; Lin CF; Hsu YS; Chang M; Chang SC Vaccine; 2019 Mar; 37(14):1994-2003. PubMed ID: 30837170 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1. Nicolodi C; Groiss F; Kiselev O; Wolschek M; Seipelt J; Muster T Vaccine; 2019 Jun; 37(28):3722-3729. PubMed ID: 31155415 [TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1. Mössler C; Groiss F; Wolzt M; Wolschek M; Seipelt J; Muster T Vaccine; 2013 Dec; 31(52):6194-200. PubMed ID: 24183981 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers. Heldens J; Hulskotte E; Voeten T; Breedveld B; Verweij P; van Duijnhoven W; Rudenko L; van Damme P; van den Bosch H Vaccine; 2014 Sep; 32(39):5118-24. PubMed ID: 24858566 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. Treanor JJ; Schiff GM; Hayden FG; Brady RC; Hay CM; Meyer AL; Holden-Wiltse J; Liang H; Gilbert A; Cox M JAMA; 2007 Apr; 297(14):1577-82. PubMed ID: 17426277 [TBL] [Abstract][Full Text] [Related]
18. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal. Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502 [TBL] [Abstract][Full Text] [Related]
19. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Talaat KR; Karron RA; Callahan KA; Luke CJ; DiLorenzo SC; Chen GL; Lamirande EW; Jin H; Coelingh KL; Murphy BR; Kemble G; Subbarao K Vaccine; 2009 Jun; 27(28):3744-53. PubMed ID: 19464558 [TBL] [Abstract][Full Text] [Related]
20. Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults. Halperin SA; Smith B; Clarke K; Treanor J; Mabrouk T; Germain M Hum Vaccin; 2005; 1(1):37-42. PubMed ID: 17038827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]